N/A
Completed N=75
Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block
Source: ClinicalTrials.gov NCT02412657 ↗Enrolled (actual)
75
Serious AEs
0.0%
Results posted
Apr 2016
Primary outcomePrimary: Duration of Analgesia — 19.1; 19.6; 11.8 hours
Summary
Interscalene brachial plexus block provides excellent but time limited analgesia. Intravenous dexamethasone increases the analgesic duration of a single-shot interscalene block with ropivacaine for shoulder arthroscopic surgery. We want to evaluate the effect of two different doses (dexamethasone 10 mg i.v. vs 4 mg i.v. vs placebo) on the analgesic duration of a single-shot inter scalene block. Our study hypothesis is that dexamethasone 4 mg i.v. is equivalent to dexamethasone10 mg i.v. in prolonging the analgesic duration of a single-shot interscalene block with ropivacaine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of Analgesia |
19.1; 19.6; 11.8 | — |
| SECONDARY Pain Scores |
— | — |
| SECONDARY Residual Motor Block |
— | — |
| SECONDARY Sleep Disturbance |
— | — |
| SECONDARY Patients Overall Satisfaction |
— | — |
Eligibility Criteria
Inclusion Criteria
- Elective shoulder arthroscopy under ropivacaine single-shot interscalene brachial plexus block anesthesia (rotator cuff repair and shoulder decompression)
- ASA I-III
- Age 18-80 years old
Exclusion Criteria
- Any contraindication to interscalene brachial plexus block anesthesia
- Interscalene brachial plexus block failure
- Known local anesthetics allergy
- Dexamethasone allergy or intolerance
- Any contraindication to acetaminophen
- Any contraindication to morphine or hydromorphone
- Brachial plexus neuropathies
- Chronic pain syndrome other than shoulder pain
- Routine use of opioid medication
- Routine use of systemic corticosteroid
- Pregnancy
- Weight below 50 kilograms
- Incapability to understand a numeric verbal pain scale
- Incapability to consent
- Patient refusal
Data sourced from ClinicalTrials.gov (NCT02412657). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.